According to MedPage Today, data from a preliminary study evaluating SHR0302, an investigational Janus kinase 1 (JAK1) inhibitor, showed promise for treating patients with moderate-to-severe atopic dermatitis (AD). Following treatment,…
Since its inception, biopharmaceutical company Reistone Biopharma Co. Ltd. ("Reistone") has worked to develop treatment options for patients with immuno-inflammatory and autoimmune conditions. Most recently, their drug candidate SHR0302,…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
